Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550271 · ClinicalTrials.gov registry record
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
A clinical trial, sponsored by AgelessRx.
- Completed
- Registry status
- 67
- Enrollment target
NCT06550271: Completed study, sponsored by AgelessRx.
NCT06550271 is a clinical trial that has completed, run by AgelessRx. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06550271 has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
Primary Outcome
define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
Interventions
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2023-12-15 |
What the finished NCT06550271 record still lists
NCT06550271 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Rapamycin is the first listed.
NCT06550271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06550271 about?
NCT06550271 is a clinical study titled "The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals". This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
What is the current status of trial NCT06550271?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2023-04-25. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT06550271?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT06550271?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI